Durvalumab and olaparib combination extends survival in advanced endometrial cancer
Updated Phase 3 DUO-E trial results presented at ESMO 2026 show that durvalumab plus olaparib after chemotherapy achieved a median ...
Updated Phase 3 DUO-E trial results presented at ESMO 2026 show that durvalumab plus olaparib after chemotherapy achieved a median ...
A retrospective study of 246 patients found that a model combining multiparametric MRI radiomics, deep learning and clinical data achieved ...
An exploratory 100-patient study found that a leakage-free Random Forest poorly classified post-treatment NGAL decline and did not establish a ...
Researchers have fused a validated blood biomarker algorithm into the standard ultrasound classification for ovarian masses, sharply improving the accuracy ...
A Brazilian study finds that abnormal p53 expression identifies recurrence risk in non-invasive high-grade endometrial cancer, while wild-type tumors show ...
A detailed case report from China shows that a rare non-hotspot POLE p.T278K mutation, alongside dual MSH6 frameshift variants and ...
Three-dimensional microvascular ultrasound revealed coexisting borderline and malignant vascular patterns in a stable ovarian cyst, guiding fertility-sparing surgery that confirmed ...
A retrospective cohort of 186 patients with seromucinous borderline ovarian tumors found that cystectomy and unilateral salpingo-oophorectomy showed no significant ...
A Dutch Delphi consensus study has produced the first patient-centered core outcome set for vulvar cancer, identifying 45 quality of ...
Theresa Werner, MD, a gynecologic oncologist and veteran clinical trials leader, has been named chief of the Division of Oncology ...
A small Chinese study using weekly cone beam CT found that the uterus shrank by over 52 percent during chemoradiotherapy ...
We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.
Bioengineer.org © Copyright 2023 All Rights Reserved.
Bioengineer.org © Copyright 2023 All Rights Reserved.